Fed Regist. 1994 Dec 14;59(239):64287-96.
The Food and Drug Administration (FDA) is issuing this final rule to implement the provisions of the Safe Medical Devices Act of 1990 (the SMDA) that require all persons who submit a premarket notification (510(k)) to provide to FDA, as part of the submission, an adequate summary (510(k) summary) of any information respecting safety and effectiveness or a statement (510(k) statement) that such information will be made available upon request by any person. This rule also implements the requirement of the SMDA that 510(k) submitters claiming substantial equivalence to a class III preamendments device for which FDA has not yet called for premarket approval submit a class III summary and certify that they have conducted a search of safety and effectiveness data. In addition, this rule amends the device regulations governing the confidentiality of certain premarket notification submissions to conform to the SMDA. This rule also provides that persons who submit a premarket notification must certify that, to the best of their knowledge, all information is truthful and accurate and that no material fact has been omitted.
美国食品药品监督管理局(FDA)发布本最终规则,以实施1990年《安全医疗器械法案》(SMDA)的相关规定。该法案要求所有提交上市前通知(510(k))的人员,在提交材料时,向FDA提供关于安全性和有效性的任何信息的充分摘要(510(k)摘要),或者提供一份声明(510(k)声明),表明此类信息将应任何人的要求提供。本规则还实施了SMDA的要求,即声称与FDA尚未要求进行上市前批准的III类修正案前器械具有实质等同性的510(k)提交者,需提交III类摘要,并证明他们已对安全性和有效性数据进行了检索。此外,本规则修订了关于某些上市前通知提交材料保密性的器械法规,以符合SMDA。本规则还规定,提交上市前通知的人员必须证明,据其所知,所有信息真实准确,且未遗漏任何重大事实。